Ying-Duo Gao

This inventor holds 26 USPTO granted patents and 4 published patent applications and 11 EPO patents, primarily in Pharmaceutical Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Children's Medical Center Corporation, Merck + Co., Inc.. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ying-Duo Gao. Retrieved from https://idiyas.com/inventor/ying-duo-gao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 4)

% Patents Active = 69.2

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 9.2

ph-index = 4

Forward Citations = 65(Granted Patents)

Location History:

Neshanic Station, NJ (US) (2000)
Meshanie Station, NJ (US) (2003 - 2008)
Edison, NJ (US) (2001 - 2012)
Holmdel, NJ (US) (2016 - 2019)

Company Filing History:

12 out of 2,405

Merck Sharp + Dohme Corp.

patents

4 out of 1,072

Children's Medical Center Corporation

Ion Pharmaceuticals, Inc.

patents

6. 2 out of 2

Nuchem Pharmaceuticals Inc.

patents

7. 1 out of 1

Merck Sharp & Dhome Corp.

patent

8. 5 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Plasma Kallikrein Inhibitors

Factor XI Activation Inhibitors

Factor XIA Inhibitors

Dipeptidyl Peptidase-IV Inhibitors

Ocular Hypertension Treatments

Cell Proliferation Modulators

Btk Inhibitors

Y5 Receptor Antagonists

Inflammatory Disease Inhibitors

Triaryl Methane Compounds

Spiro-Indolines

Substituted Benzamides

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

2. 12428397 - Factor XI activation inhibitors (2025-09-30),

3. 10214512 - Factor XIA inhibitors (2019-02-26),

4. 10123995 - Factor XIa inhibitors (2018-11-13),

5. 10093683 - Factor XIa inhibitors (2018-10-09),

6. 10081617 - Factor XIa inhibitors (2018-09-25),

7. 10011585 - Factor XIa inhibitors (2018-07-03),

8. 9975874 - Factor XIa inhibitors (2018-05-22),

9. 9868727 - Factor XIa inhibitors (2018-01-16),

10. 9481682 - Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors (2016-11-01),

11. 8153626 - Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators (2012-04-10),

12. 7956061 - Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes (2011-06-07),

13. 7659408 - Pyrazole carboxamides as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 (2010-02-09),

14. 7531573 - Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease (2009-05-12),

15. 7482336 - Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes (2009-01-27),

Title: A Spotlight on Ying-Duo Gao: Innovator in Pharmaceutical Sciences

Introduction

Ying-Duo Gao, an accomplished inventor based in Holmdel, NJ, is known for his significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 24 patents, he has made remarkable advancements in the development of therapeutic compounds, particularly in the area of coagulation research.

Latest Patents

Among his latest inventions are notable patents focusing on Factor XIA inhibitors. These patents describe a compound of Formula (I) and pharmaceutical compositions that encompass one or more of these compounds. They detail methods for using these compounds to treat or prevent thromboses, embolisms, hypercoagulability, or fibrotic changes. Moreover, these compounds are identified as selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein, paving the way for potentially transformative treatments for patients facing serious clotting disorders.

Career Highlights

Throughout his career, Ying-Duo Gao has worked with renowned companies, particularly Merck Sharp & Dohme Corporation. His tenure at Merck demonstrates his commitment to advancing pharmaceutical research and innovation. His extensive experience has not only contributed to his personal achievements but has also played a crucial role in the development of therapies that benefit the medical community and patients alike.

Collaborations

Collaboration plays a significant role in Gao's career, as he has had the opportunity to work alongside esteemed colleagues such as Carlo Brugnara and Jose Alberto Halperin. These partnerships have likely catalyzed innovation and fostered a collaborative environment conducive to groundbreaking discoveries in pharmaceuticals.

Conclusion

In summary, Ying-Duo Gao's contributions to the field of pharmaceutical sciences are commendable. With a focus on Factor XIA inhibitors and a history of collaboration with key figures in the industry, he continues to impact the way medical professionals approach coagulation disorders. As his work progresses, the innovations stemming from his patents hold the promise of enhancing patient care and treatment outcomes.

Profile summary based on public USPTO records.